G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma

Engineered T cells transiently expressing tumor-targeting receptors are an attractive form of engineered T cell therapy as they carry no risk of insertional mutagenesis or long-term adverse side-effects. However, multiple rounds of treatment are often required, increasing patient discomfort and cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Maxine S. Y., Reales-Calderon, Jose Antonio, Ow, Jin Rong, Aw, Joey J. Y., Tan, Damien, Vijayakumar, Ragavi, Ceccarello, Erica, Tabaglio, Tommaso, Lim, Yan Ting, Chien, Wang Loo, Lai, Fritz, Tanoto, Anthony Tan, Chen, Qingfeng, Sobota, Radoslaw M., Adriani, Giulia, Bertoletti, Antonio, Guccione, Ernesto, Pavesi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894856/
https://www.ncbi.nlm.nih.gov/pubmed/36732506
http://dx.doi.org/10.1038/s41467-023-36160-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894856/
https://www.ncbi.nlm.nih.gov/pubmed/36732506
http://dx.doi.org/10.1038/s41467-023-36160-5

Ejemplares similares